{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:59:49Z","timestamp":1760299189317,"version":"3.37.3"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003825","name":"Magyar Tudom\u00e1nyos Akad\u00e9mia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.pcad.2015.08.008","type":"journal-article","created":{"date-parts":[[2015,8,8]],"date-time":"2015-08-08T11:36:30Z","timestamp":1439033790000},"page":"278-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Platelet Reactivity: Is There a Role to Switch?"],"prefix":"10.1016","volume":"58","author":[{"given":"D\u00e1niel","family":"Aradi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9la","family":"Merkely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e1s","family":"Kom\u00f3csi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2015.08.008_bb0005","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"Windecker","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2015.08.008_bb0010","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jacc.2014.03.049","article-title":"Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis","volume":"64","author":"Halvorsen","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2015.08.008_bb0015","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Antithrombotic Trialists","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2015.08.008_bb0020","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2015.08.008_bb0025","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/eurheartj\/ehr204","article-title":"Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology","volume":"32","author":"Steg","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2015.08.008_bb0030","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2015.08.008_bb0035","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/eurheartj\/eht375","article-title":"Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention","volume":"35","author":"Aradi","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2015.08.008_bb0040","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.thromres.2013.10.008","article-title":"Evaluation of laboratory methods routinely used to detect the effect of aspirin against new reference methods","volume":"133","author":"Kovacs","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.pcad.2015.08.008_bb0045","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2012.03.050","article-title":"Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study","volume":"60","author":"Alexopoulos","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2015.08.008_bb0050","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jcin.2014.04.020","article-title":"Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study","volume":"7","author":"Palmerini","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2015.08.008_bb0055","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1160\/TH12-08-0608","article-title":"Evaluating the clinical usefulness of platelet function testing: considerations for the proper application and interpretation of performance measures","volume":"109","author":"Dahlen","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pcad.2015.08.008_bb0060","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jama.2010.181","article-title":"Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation","volume":"303","author":"Breet","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2015.08.008_bb0065","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1160\/TH14-05-0449","article-title":"Platelet function testing in acute cardiac care \u2014 is there a role for prediction or prevention of stent thrombosis and bleeding?","volume":"113","author":"Aradi","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pcad.2015.08.008_bb0070","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study","volume":"382","author":"Stone","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2015.08.008_bb0075","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","article-title":"Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention","volume":"36","author":"Aradi","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2015.08.008_bb0080","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.114.002106","article-title":"Incremental value of platelet reactivity over a risk score of clinical and procedural variables in predicting bleeding after percutaneous coronary intervention via the femoral approach: development and validation of a new bleeding risk score","volume":"8","author":"Mangiacapra","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2015.08.008_bb0085","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2015.08.008_bb0090","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2015.08.008_bb0095","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","volume":"59","author":"Trenk","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2015.08.008_bb0100","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2015.08.008_bb0105","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/jama.2011.1332","article-title":"High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI","volume":"306","author":"Parodi","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2015.08.008_bb0110","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jacc.2013.12.023","article-title":"Optimizing P2Y-receptor inhibition in acute coronary syndrome patients based on platelet function testing: impact of prasugrel and high-dose clopidogrel","volume":"63","author":"Aradi","year":"2014","journal-title":"J Am Coll Cardiol"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062015000675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062015000675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T19:10:02Z","timestamp":1617649802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062015000675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0033062015000675"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2015.08.008","relation":{},"ISSN":["0033-0620"],"issn-type":[{"type":"print","value":"0033-0620"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Platelet Reactivity: Is There a Role to Switch?","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2015.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}